The FDA has issued safety communications regarding compounded GLP-1 receptor agonists, including tirzepatide and semaglutide, warning about adverse events from bacterial contamination, incorrect dosing, and use of improper ingredients
People with inflammatory joint conditions and OA-type pain seem to have a somewhat higher rate of positive reports, which aligns with the OA-specific evidence
Standard lab panels include hemoglobin A1c, fasting glucose, lipid panels, liver enzymes, kidney function markers, thyroid function, and complete blood count
This strategy involves administering smaller-than-standard doses to harness the metabolic and protective benefits of GLP-1 activation while minimizing side effects, cost, and rapid weight loss
and Regional Government of Catalonia, Spain (2017-SGR-1229)